• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>RPC

Related Topics

  1. Tootsie Roll Industries
  2. Blackrock
  3. BlackRock PA Strategic Municipal
  4. State Street Corporation
  5. M & T Bank
  6. Facebook

Popular Topics

  1. Adobe Systems
  2. Vanda Pharmaceuticals
  3. Nektar Therapeutics
  4. Deutsche Bank
  5. Emerging Markets

RPC

RPC RES

Last Price$14.10Day Change (%)-1.05%
Open Price$14.28Day Change ($)-0.15
Day Range13.94–14.3052-Week Range9.97–17.40

As of Wed 06/19/2013 04:00 PM EDT | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. RPC RES Q4 2012 Earnings Call Transcript

    Good morning and thank you for joining us for RPC , Inc.'s Fourth Quarter and Year End 2012 Earnings Conference Call. Today's call will be hosted by Rick Hubell, President and CEO and Ben Palmer, Chief Financial Officer. Also present is Jim Landers, Vice President of Corporate Finance. At this time ...

  2. Internet Society Statement on the Importance of Open Global Dialogue Regarding Online Privacy

    Internet Society Statement on the Importance of Open Global Dialogue Regarding Online Privacy

  3. Fitch Affirms MSCI 2004-HQ4

    Fitch Affirms MSCI 2004-HQ4

  4. Nordson MARCH Hosts Free Plasma Technology for PCB Processes Seminar in Ontario, Canada on June 25

    Nordson MARCH Hosts Free Plasma Technology for PCB Processes Seminar in Ontario, Canada on June 25

  5. PGE Announces New Power Plants, Transmission Capacity Proposal

    PGE Announces New Power Plants, Transmission Capacity Proposal

  6. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical ...

    Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting

  7. Fitch Affirms BSCMS 1999-WF2

    Fitch Affirms BSCMS 1999-WF2

  8. OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

    OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

  9. Travis Pastrana Announces Inaugural Nitro Circus Live North American Tour

    Travis Pastrana Announces Inaugural Nitro Circus Live North American Tour

  10. Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility

    Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility

12
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.